1. Главная
  2. Ресурсы
  3. Библиотечный поиск
Idiopathic PulmonaryFibrosis (an Update)and ProgressivePulmonary Fibrosis inAdults: An OfficialATS/ERS/JRS/ALATClinical PracticeGuideline Ganesh RaghuMartine Rémy‐JardinLuca Richeldi2022 год

Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
статья из журнала

Полный текстСтраница публикацииПубликация в OpenAlex
Аннотация: Background: This American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Asociación Latinoamericana de Tórax guideline updates prior idiopathic pulmonary fibrosis (IPF) guidelines and addresses the progression of pulmonary fibrosis in patients with interstitial lung diseases (ILDs) other than IPF. Methods: A committee was composed of multidisciplinary experts in ILD, methodologists, and patient representatives. 1) Update of IPF: Radiological and histopathological criteria for IPF were updated by consensus. Questions about transbronchial lung cryobiopsy, genomic classifier testing, antacid medication, and antireflux surgery were informed by systematic reviews and answered with evidence-based recommendations using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach. 2) Progressive pulmonary fibrosis (PPF): PPF was defined, and then radiological and physiological criteria for PPF were determined by consensus. Questions about pirfenidone and nintedanib were informed by systematic reviews and answered with evidence-based recommendations using the GRADE approach. Results:1) Update of IPF: A conditional recommendation was made to regard transbronchial lung cryobiopsy as an acceptable alternative to surgical lung biopsy in centers with appropriate expertise. No recommendation was made for or against genomic classifier testing. Conditional recommendations were made against antacid medication and antireflux surgery for the treatment of IPF. 2) PPF: PPF was defined as at least two of three criteria (worsening symptoms, radiological progression, and physiological progression) occurring within the past year with no alternative explanation in a patient with an ILD other than IPF. A conditional recommendation was made for nintedanib, and additional research into pirfenidone was recommended. Conclusions: The conditional recommendations in this guideline are intended to provide the basis for rational, informed decisions by clinicians.
Год издания: 2022
Авторы: Ganesh Raghu, Martine Rémy‐Jardin, Luca Richeldi, Carey C. Thomson, Yoshikazu Inoue, Takeshi Johkoh, Michael Kreuter, David A. Lynch, Toby M. Maher, Fernando J. Martínez, María Molina‐Molina, Jeffrey L. Myers, Andrew G. Nicholson, Christopher J. Ryerson, Mary E. Strek, Lauren Troy, Marlies Wijsenbeek, Manoj J. Mammen, Tanzib Hossain, Brittany D. Bissell, Derrick D. Herman, Stephanie Hon, Fayez Kheir, Yet H. Khor, Madalina Macrea, Katerina M. Antoniou, Demosthenes Bouros, Ivette Buendía-Roldán, Fabián Caro, Bruno Crestani, Lawrence Ho, Julie Morisset, Amy L. Olson, Anna J. Podolanczuk, Venerino Poletti, Moisés Selman, T. Ewing, Stephen E. Jones, Shandra L. Knight, Marya Ghazipura, Kevin C. Wilson
Издательство: American Thoracic Society
Источник: American Journal of Respiratory and Critical Care Medicine
Ключевые слова: Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis, Occupational and environmental lung diseases, Occupational exposure and asthma
Другие ссылки: American Journal of Respiratory and Critical Care Medicine (HTML)
Scopus (Elsevier) (PDF)
Scopus (Elsevier) (HTML)
EUR Research Repository (Erasmus University Rotterdam) (PDF)
EUR Research Repository (Erasmus University Rotterdam) (HTML)
PubMed Central (HTML)
PubMed (HTML)